When was Quantumcyte founded?

Quantumcyte was founded in 2013 and raised its 1st funding round 4 years after it was founded.

Where is Quantumcyte located?

Quantumcyte is headquartered in Sunnyvale, United States.

Who is the current CEO of Quantumcyte?

John Butler of Quantumcyte. They have also founded 1 company and are an angel investors in 1 startup.

How many employees does Quantumcyte have?

As of Jul 01, 2024, the latest employee count at Quantumcyte is 7.

Is Quantumcyte a funded company?

Quantumcyte is a funded company, having raised a total of $1.3M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 31, 2017.

When was the latest funding round of Quantumcyte?

Quantumcyte's latest funding was a $***** Seed round on Aug 15, 2023, with participation from 0 investor. Its primary sector is Biopharma Outsourcing. In United States, the Biopharma Outsourcing sector has seen $260M in funding in 2026 to date.

Where does Quantumcyte rank among its competitors?

Quantumcyte ranks 7th amongst 85 active competitors, of which 12 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Genoskin, which secured $5.4M in Sep, 2025.

Who are the top competitors of Quantumcyte?

Quantumcyte's top competitors include Magnitude Biosciences, Genoskin and Reaction Biology. Among them, Genoskin secured the most recent funding round in September, 2025.

Quantumcyte - 2026 Company Profile, Team, Funding & Competitors

Quantumcyte is a seed company based in Sunnyvale (United States), founded in 2013 by John Butler. It operates as a Drug assay system to treat cancer. Quantumcyte has raised $1.3M in funding from IndieBio. The company has 85 active competitors, including 12 funded and 8 that have exited. Its top competitors include companies like Magnitude Biosciences, Genoskin and Reaction Biology.

Company Details

Website: www.quantumcyte.com/
Social

Key Metrics

Founded Year

2013

Location

Sunnyvale, United States

Stage

Seed

Total Funding

$1.3M in 2 rounds

Latest Funding Round

Seed, Aug 15, 2023, $*****

Investors

IndieBio & 1 more

Ranked

7^th among 85 active competitors

Employee Count

7 as on Jul 01, 2024

Similar Companies

Magnitude Biosciences & 94 more

View Quantumcyte's full profile

Quantumcyte has raised a total funding of $1.3M over 2 rounds. Its first funding round was on May 31, 2017. Quantumcyte has 2 institutional investors.

Here is the list of recent funding rounds of Quantumcyte:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 15, 2023	1113141	Seed	3035426	9867798	2424130	3916334
May 31, 2017	9175713	Seed	8913139	4327142	IndieBio	7241281

Access funding benchmarks and valuations. Sign up today!

View details of Quantumcyte's funding rounds and investors

The founders of Quantumcyte is John Butler. John Butler is the CEO of Quantumcyte.

Here are the details of Quantumcyte's key team members:

John Butler: Co-Founder & CEO of Quantumcyte. They are also an angel investor in 1 startup and serve on the board of 1 company.
Contact Info: 1 email address and 1 phone number

View details of Quantumcyte's Founder profiles and Board Members

Quantumcyte's employee count trend

Quantumcyte has 7 employees as of Jul 24. Here is Quantumcyte's employee count trend over the years:

Uncover Quantumcyte's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Quantumcyte include Magnitude Biosciences, Genoskin and Reaction Biology. Here is the list of Top 10 competitors of Quantumcyte, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Magnitude Biosciences 2018, Durham (United Kingdom), Seed	Provider of cell-free in vitro assay for drug discovery companies	$2.6M	Northstar Ventures, Saker Capital & 10 others	58/100
2nd	Genoskin 2011, Toulouse (France), Series A	In vitro human skin models for preclinical toxicity and efficacy testing	$5.4M	OCCTE, Caisse D Epargne & 7 others	53/100
3rd	Reaction Biology 2001, United States, Late Stage	In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling	-	Cobepa, CYwP Funds & 6 others	45/100
4th	ACE Research 2016, Kisumu (Kenya), Unfunded	Provider of contract research organization services for clinical trials	-	-	43/100
5th	Radiant Research Services 2009, Bengaluru (India), Acquired	Preclinical in vitro testing and development services	-	-	39/100
6th	Discovery Biomed 2007, Birmingham (United Kingdom), Acquired	Contract research organization	-	NIDDK, Greer Capital Advisors & 4 others	39/100
7th	Quantumcyte 2013, Sunnyvale (United States), Seed	Drug assay system to treat cancer	$1.3M	Bayes Ventures, IndieBio	39/100
8th	Scion Life Sciences 2022, New York (United States), Unfunded	Venture capital firm building biotechnology companies to develop new medicines	-	-	36/100
9th	Syntax Bio 2018, Chicago (United States), Unfunded	Preclinical-stage biotech company that develops innovative stem cell-derived therapies by leveraging CRISPR technology	-	-	35/100
10th	Leadgene Biomedical 2013, Tainan (Taiwan), Unfunded	CRO offers invitro drug testing services	-	-	35/100